Table 6.

Management of patients attending outpatient clinic with moderately to severely active inflammatory bowel disease in the scenario of asymptomatic severe acute respiratory syndrome coronavirus 2 infection or confirmed or suspected coronavirus disease 2019 [11, 154,161,162].

	Management
Asymptomatic infection necessary with SARS-CoV-2	1) Restrict the use of prednisone ≤ 40 mg/d if necessary; (2) Avoid immunomodulators and to facitinib; with SARS-CoV-2 (3) Escalate to biologics as (preferably in monotherapy); and (4) Thromboprophylaxis
Mild COVID-19	1) Restrict the use of prednisone ≤ 40 mg/d if necessary; (2) Avoid starting or stopping, if in use, immunomodulators, and tofacitinib; (3) Escalate to biologics and dose optimization as necessary (preferably in monotherapy); and (4) Thromboprophylaxis
COVID-19 with pulmonary Escalate involvement without SHS with infectious	(1) Restrict the use of prednisone ≤ 40 mg/d if necessary; (2) Avoid starting or stopping pulmonary involvement immunomodulators, and tofacitinib; (3) to biologics and dose optimization as without SHS necessary (preferably) in monotherapy based on balance of benefits and risks; consultation diseases expert for possible COVID-19 treatment with antiviral or experimental anticitokine therapy; and (4) Thromboprophylaxis

Immunomodulators refer to thiopurines and methotrexate. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 2019; SHS: Systemic hyperinflammation syndrome